Profound Medical Posts Record Q3 2026 Revenue, Beating Estimates…

Event summary

Profound Medical expects Q3 2026 revenue of $9.8M–$10.0M, up 85–89% YoY and 292–300% QoQ.
Revenue exceeds Bloomberg consensus estimate of $6.78M by 45–47%.
Gross margin expected to exceed 70% for the third consecutive quarter.
Full Q3 2026 results to be released on November 5, 2026.

The big picture

Profound Medical's record-breaking Q3 2026 revenue highlights the growing commercial momentum behind its interventional MRI (iMRI) procedures. The company's ability to significantly outperform analyst expectations suggests strong market demand for its TULSA-PRO and Sonalleve platforms. This performance positions Profound as a key player in the minimally invasive prostate ablation and pain palliation markets, where precision and personalized treatment strategies are increasingly valued.

What we're watching

Revenue Sustainability: Whether Profound can maintain this growth pace into Q4 2026 and beyond.
Commercial Momentum: How the company scales adoption of its iMRI procedures across new customer accounts.
Operational Efficiency: The pace at which Profound improves gross margins through commercial operations and scale.